CVC Capital Partners considers selling some assets after successfully acquiring Recordati

Investing.com – Bloomberg reported on Friday that if CVC Capital Partners Plc completes its 10.9 billion euro ($12.5 billion) acquisition of Italian pharmaceutical company Recordati SpA, the investment firm is considering a range of options, including potential asset divestitures.

According to the report, one possible alternative would be for the firm to consider selling Recordati’s rare disease business unit. The report also said that CVC may consider selling other assets of the pharmaceutical company.

Recordati said on Thursday that it had received a takeover offer of 52 euros per share, including a dividend, from its largest shareholder, representing a 12% premium to the pharmaceutical company’s Wednesday closing price.

CVC is seeking to take Recordati private. The company had previously explored selling its stake in the pharmaceutical company. Current deliberations are still in an early stage, and details could still change.

These potential moves would give CVC more flexibility to reshape the company after Recordati is delisted, and would help it unlock more value from areas such as the rare disease business unit, which is developing high-margin therapies for rare conditions such as Cushing’s syndrome and hyperammonemia.

Since the private equity firm acquired the controlling company of the founding family in 2018, it has effectively been steering Recordati’s development.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.